1. Home
  2. LCFY vs SNGX Comparison

LCFY vs SNGX Comparison

Compare LCFY & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCFY
  • SNGX
  • Stock Information
  • Founded
  • LCFY 2009
  • SNGX 1987
  • Country
  • LCFY Australia
  • SNGX United States
  • Employees
  • LCFY N/A
  • SNGX N/A
  • Industry
  • LCFY
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LCFY
  • SNGX Health Care
  • Exchange
  • LCFY Nasdaq
  • SNGX Nasdaq
  • Market Cap
  • LCFY 5.4M
  • SNGX 6.5M
  • IPO Year
  • LCFY 2022
  • SNGX 1987
  • Fundamental
  • Price
  • LCFY $9.11
  • SNGX $1.37
  • Analyst Decision
  • LCFY
  • SNGX
  • Analyst Count
  • LCFY 0
  • SNGX 0
  • Target Price
  • LCFY N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • LCFY 4.8M
  • SNGX 147.3K
  • Earning Date
  • LCFY 07-07-2025
  • SNGX 08-08-2025
  • Dividend Yield
  • LCFY N/A
  • SNGX N/A
  • EPS Growth
  • LCFY N/A
  • SNGX N/A
  • EPS
  • LCFY N/A
  • SNGX N/A
  • Revenue
  • LCFY $2,668,385.00
  • SNGX $2,342.00
  • Revenue This Year
  • LCFY N/A
  • SNGX N/A
  • Revenue Next Year
  • LCFY N/A
  • SNGX N/A
  • P/E Ratio
  • LCFY N/A
  • SNGX N/A
  • Revenue Growth
  • LCFY N/A
  • SNGX N/A
  • 52 Week Low
  • LCFY $2.24
  • SNGX $1.31
  • 52 Week High
  • LCFY $13.98
  • SNGX $14.83
  • Technical
  • Relative Strength Index (RSI)
  • LCFY 29.43
  • SNGX 23.71
  • Support Level
  • LCFY $2.62
  • SNGX $1.31
  • Resistance Level
  • LCFY $2.93
  • SNGX $1.95
  • Average True Range (ATR)
  • LCFY 0.27
  • SNGX 0.07
  • MACD
  • LCFY -0.04
  • SNGX -0.05
  • Stochastic Oscillator
  • LCFY 2.52
  • SNGX 9.56

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: